AXIOS February 27, 2025
Last week, President Trump threatened tariffs on pharmaceuticals if manufacturers don’t relocate operations to the U.S. On Wednesday, the CEO of Eli Lilly stood with Trump’s commerce secretary in Washington, D.C., to announce a $27 billion plan to build four manufacturing “mega-sites” in the U.S.
Why it matters: The commitment illustrates the dance much of Big Pharma is engaged in as it tries to make inroads with a new administration bent on reshoring business activity and reducing dependence on China.
The big picture: Reshoring pharmaceutical manufacturing would be a shift for the industry, which still sources most drug ingredients from overseas and has seen its global supply chains buckle from disease outbreaks and natural disasters. Now, political winds from Washington...
Today's Sponsors
Today's Sponsor